Atossa Therapeutics Inc.

ATOS | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.30

+$0.05 (+2.22%)

Sep 22, 2026, 11:03 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.22%

(1D)

Rating

Updated: Aug 26, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $22.94M

1D Range

2.30 2.43

52W Range

1.70 19.35

Valuation (TTM)

PE -0.52

PB 0.84

EV/EBITDA 0.12

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $42.50

Cash Flow

FCF Yield -159.4%

SBC Adj. FCF Yield -172.0%

SBC Impact -7.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -17.2% | -9.3%

FCF 3Y | 5Y -32.2% | -16.9%

Returns

ROA -116.8%

ROE -103.0%

ROIC -146.3%

Financial Health

Net Cash

$26.09M

Current Ratio 5.69

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, espec...

Sector Healthcare

Industry Biotechnology

Employees 16

IPO Date Nov 7, 2012

Website www.atossatherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$42.50

Upside

+1747.83%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞